News Articles and Montana BioScience Alliance Newsletters


Montana Tech was recently awarded a five-year, $24 million grant from the Army Research Laboratory to develop a program called “Materials Technology for Rare Earth Elements Processing.” This program, which responds to a critical national need to develop a supply chain for rare earth elements, is a multidisciplinary effort that will use Montana as a model for locating rare earth elements in primary and secondary sources.

Emory Hoelscher-Hull was recently awarded a prestigious public health grant based on her research into water quality in Montana; Pilar Santos was one of four winners of the 2022 Association of Environmental Health Academic Program student research competition, and Sarah Warnke was a runner-up in the competition. All three students were mentored with support from Montana NSF EPSCoR by Dr. Mari Eggers, an Assistant Research Professor in the Department of Microbiology and Immunology.

Montana’s Tonix Pharmaceuticals has announced the design of a new Phase 2 clinical trial of TNX-1300 for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial. TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support of the use of TNX-1300 as a treatment for cocaine intoxication. The company plans to submit the new protocol to the […]

Montana BioScience Alliance and BIO
July 2, 2022

Covid-19 opened the world’s eyes to the wonders of biotechnology. Unfortunately, though, coverage of the industry isn’t always the best. To provide more information about the ways bioscience is curing disease, solving climate change, and feeding and fueling the world in more sustainable ways, the Montana BioScience Alliance is joining with BIO to develop easy-to-read and easy-to-share news articles by independent journalists, editors, and content creators, as well as smart analysis by BIO experts. You can find it now on Bio.News.

Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO.


May 22, 2023

Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.

National Institutes of Health
May 5, 2023

Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more

National Institutes of Health
March 27, 2023

SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]

FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.

Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.


April 28, 2023

View the Spring 2023 Newsletter now!

February 2, 2023

View the Winter 2022 Newsletter now!